Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to halt kidney damage in IgA nephropathy

NCT ID NCT06797518

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests iptacopan, an oral drug, in 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to see if the drug reduces signs of inflammation and damage over 9 months. The goal is to understand if iptacopan can slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iptacopan (oral capsule)
What this could lead to
If successful, this could point toward a treatment that slows kidney damage in IgA nephropathy patients.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. The main focus is on biomarker changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS, IGA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis IgA nephropathy, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLOMERULONEPHRITIS, IGA IMMUNOGLOBULIN A NEPHROPATHY

Contacts and locations

Locations

  • CaRe Research

    RECRUITING

    Chubbuck, Idaho, 83202, United States

  • Central Florida Kidney Specialists

    RECRUITING

    Orlando, Florida, 32806, United States

  • DaVita Clinical Research

    RECRUITING

    Las Vegas, Nevada, 89146, United States

  • Georgia Nephrology Research Inst

    RECRUITING

    Lawrenceville, Georgia, 30046, United States

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, 1425, Argentina

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, C1280AEB, Argentina

  • Novartis Investigative Site

    RECRUITING

    Córdoba, Córdoba Province, X5016KET, Argentina

  • Novartis Investigative Site

    RECRUITING

    Ashdod, 7747629, Israel

  • Novartis Investigative Site

    RECRUITING

    Hadera, 3820302, Israel

  • Novartis Investigative Site

    RECRUITING

    Haifa, 3109601, Israel

  • Novartis Investigative Site

    RECRUITING

    Nahariya, 2210001, Israel

  • Novartis Investigative Site

    RECRUITING

    Kuala Lumpur, Kuala Lumpur, 50586, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Kuala Lumpur, Selangor, 43000, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Riyadh, 11211, Saudi Arabia

  • OSU Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Prolato Clinical Research Center

    RECRUITING

    Houston, Texas, 77054, United States

  • UCLA Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.